Sullivan Timothy Eugene (CIK 1707000) reported 29 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-05-14). Recent activity: Sell APLS (140,945 shares), Sell APLS (58,140 shares), Buy APLS (41,250 shares), Sell APLS (41,250 shares), Buy APLS (30,620 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) | Chief Financial Officer | Sell | 140,945 | $0 |
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) | Chief Financial Officer | Sell | 58,140 | $0 |
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) | Chief Financial Officer | Buy | 41,250 | $0 |
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) | Chief Financial Officer | Sell | 41,250 | $0 |
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) | Chief Financial Officer | Buy | 30,620 | $0 |
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) | Chief Financial Officer | Sell | 30,620 | $0 |
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) | Chief Financial Officer | Buy | 29,070 | $0 |
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) | Chief Financial Officer | Sell | 71,492 | $0 |
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) | Chief Financial Officer | Buy | 58,140 | $0 |
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) | Chief Financial Officer | Sell | 58,140 | $0 |
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) | Chief Financial Officer | Sell | 6,872 | $0 |
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) | Chief Financial Officer | Sell | 11,874 | $0 |
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) | Chief Financial Officer | Sell | 34,447 | $0 |
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) | Chief Financial Officer | Sell | 29,070 | $0 |
| 2026-04-20 | Apellis Pharmaceuticals, Inc. (APLS) | Chief Financial Officer | Sell | 11,096 | $0 |
| 2026-04-20 | Apellis Pharmaceuticals, Inc. (APLS) | Chief Financial Officer | Buy | 11,096 | $0 |
| 2026-01-30 | Apellis Pharmaceuticals, Inc. (APLS) | Chief Financial Officer | Buy | 58,140 | $0 |
| 2026-01-23 | Apellis Pharmaceuticals, Inc. (APLS) | Chief Financial Officer | Sell | 10,287 | $223,948 |
| 2026-01-21 | Apellis Pharmaceuticals, Inc. (APLS) | Chief Financial Officer | Sell | 2,892 | $57,233 |
| 2026-01-15 | Apellis Pharmaceuticals, Inc. (APLS) | Chief Financial Officer | Sell | 3,856 | $85,565 |
| 2025-10-23 | Apellis Pharmaceuticals, Inc. (APLS) | Chief Financial Officer | Buy | 10,000 | $100,300 |
| 2025-10-23 | Apellis Pharmaceuticals, Inc. (APLS) | Chief Financial Officer | Sell | 10,000 | $280,300 |
| 2025-09-10 | Apellis Pharmaceuticals, Inc. (APLS) | Chief Financial Officer | Sell | 10,000 | $278,300 |
| 2025-09-10 | Apellis Pharmaceuticals, Inc. (APLS) | Chief Financial Officer | Buy | 15,000 | $150,450 |
| 2025-09-10 | Apellis Pharmaceuticals, Inc. (APLS) | Chief Financial Officer | Sell | 32,729 | $911,830 |
Source: SEC Form 4 filings · as of 2026-05-14